UNDERWRITING AGREEMENT between LANTERN PHARMA INC and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters LANTERN PHARMA INC.Underwriting Agreement • May 19th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • New York
The undersigned, Lantern Pharma Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being a subsidiary or affiliates of Lantern Pharma Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Lock-Up AgreementLock-Up Agreement • May 19th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 19th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This AMENDMENT TO EMPLOYMENT AGRREEMENT amends the Employment Agreement, dated as of the 23rd day of July, 2018 (the “Employment Agreement”), between Lantern Pharma Inc. (the “Company”), and Panna Sharma (“Executive”) is entered into as of May 18, 2020, and will become effective upon the Company’s initial public offering (“IPO”) and listing of its common stock on the NASDAQ Stock Market (the “Effective Date”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • May 19th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
This EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into to be effective as of first day of business after the closing of the I.P.O. (defined below) (the “Effective Date”), between Lantern Pharma Inc. (the “Company”), and KISHOR G. BHATIA (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties.” The term I.P.O. shall mean the initial public offering of the Company.
LANTERN PHARMA INC. Form of Amendment to Preferred Stock WarrantLantern Pharma Inc. • May 19th, 2020 • Pharmaceutical preparations
This Amendment to Preferred Stock Warrant, dated as of _________2020 (“Amendment”), by and between Lantern Pharma Inc., a Delaware corporation (the “Issuer”), and ______________ (“Holder”).
